Now showing items 515-534 of 687

    • Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. 

      Sestak, I; Martín, M; Dubsky, P; Kronenwett, R; Rojo, F; Cuzick, J; Filipits, M; Ruiz, A; Gradishar, W; Soliman, H; Schwartzberg, L; Buus, R; Hlauschek, D; Rodríguez-Lescure, A; Gnant, M (2019-07)
      PURPOSE:EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we ...
    • Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System 

      Kuiper, R; Van Vliet, MH; van Beers, EH; Broijl, A; Mulligan, G; Avet-Loiseau, H; Gregory, W; Morgan, GJ; Goldschmidt, H; Lokhorst, H; van Duin, M; Sonneveld, P (AMER SOC HEMATOLOGY, 2014-12-06)
    • Predictors of response to aromatase inhibitors. 

      Anderson, H; Bulun, S; Smith, I; Dowsett, M (2007-08)
      Aromatase inhibitors are now considered to be part of the endocrine treatment for most hormone receptor-positive breast cancer in post-menopausal women for both early and advanced disease. Despite the impressive efficacy ...
    • Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia 

      Osuji, N; Matutes, E; Dearden, C; Catovsky, D (BLACKWELL PUBLISHING LTD, 2005-03)
      The effect of pregnancy on T-cell large granular lymphocyte (LGL) leukaemia has not been previously described. We retrospectively reviewed the clinical features of three patients with T-cell LGL leukaemia; each of them had ...
    • Primary Bone Marrow Lymphoma: An Uncommon Extranodal Presentation of Aggressive Non-Hodgkin Lymphomas 

      Matutes, E (2012-02)
      Bone marrow involvement by lymphoma is considered a systemic dissemination of the disease arising elsewhere, although some tumors may arise primarily in the bone marrow microenvironment. Primary bone marrow lymphoma (PBML) ...
    • Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer. 

      Jenks, AD; Vyse, S; Wong, JP; Kostaras, E; Keller, D; Burgoyne, T; Shoemark, A; Tsalikis, A; de la Roche, M; Michaelis, M; Cinatl, J; Huang, PH; Tanos, BE (2018-06)
      Primary cilia are microtubule-based organelles that detect mechanical and chemical stimuli. Although cilia house a number of oncogenic molecules (including Smoothened, KRAS, EGFR, and PDGFR), their precise role in cancer ...
    • Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis. 

      May-Wilson, S; Sud, A; Law, PJ; Palin, K; Tuupanen, S; Gylfe, A; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Al-Tassan, NA; Palles, C; Farrington, SM; Timofeeva, MN; Meyer, BF; Wakil, SM; Campbell, H; Smith, CG; Idziaszczyk, S; Maughan, TS; Fisher, D; Kerr, R; Kerr, D; Passarelli, MN; Figueiredo, JC; Buchanan, DD; Win, AK; Hopper, JL; Jenkins, MA; Lindor, NM; Newcomb, PA; Gallinger, S; Conti, D; Schumacher, F; Casey, G; Aaltonen, LA; Cheadle, JP; Tomlinson, IP; Dunlop, MG; Houlston, RS (2017-10)
      BACKGROUND:While dietary fat has been established as a risk factor for colorectal cancer (CRC), associations between fatty acids (FAs) and CRC have been inconsistent. Using Mendelian randomisation (MR), we sought to evaluate ...
    • The prognostic effects of somatic mutations in ER-positive breast cancer. 

      Griffith, OL; Spies, NC; Anurag, M; Griffith, M; Luo, J; Tu, D; Yeo, B; Kunisaki, J; Miller, CA; Krysiak, K; Hundal, J; Ainscough, BJ; Skidmore, ZL; Campbell, K; Kumar, R; Fronick, C; Cook, L; Snider, JE; Davies, S; Kavuri, SM; Chang, EC; Magrini, V; Larson, DE; Fulton, RS; Liu, S; Leung, S; Voduc, D; Bose, R; Dowsett, M; Wilson, RK; Nielsen, TO; Mardis, ER; Ellis, MJ (2018-09-04)
      Here we report targeted sequencing of 83 genes using DNA from primary breast cancer samples from 625 postmenopausal (UBC-TAM series) and 328 premenopausal (MA12 trial) hormone receptor-positive (HR+) patients to determine ...
    • Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients 

      Parry-Jones, N; Matutes, E; Gruszka-Westwood, AM; Swansbury, GJ; Wotherspoon, AC; Catovsky, D (2003-03)
      Splenic lymphoma with villous lymphocytes (SLVL) is a low-grade B-cell lymphoma defined in the World Health Organization classification as the leukaemic form of splenic marginal zone lymphoma. Presenting features and ...
    • Prognostic Impact of Fascin-1 (FSCN1) in Epithelial Ovarian Cancer 

      Gevensleben, Heidrun (2013-02)
      Background: Fascin-1 (FSCN1) plays an important role in cancer development and is associated with invasion and metastasis. Therefore, we explored the expression and localization of FSCN1 in epithelial ovarian cancer (EOC). ...
    • Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. 

      Abubakar, M; Orr, N; Daley, F; Coulson, P; Ali, HR; Blows, F; Benitez, J; Milne, R; Brenner, H; Stegmaier, C; Mannermaa, A; Chang-Claude, J; Rudolph, A; Sinn, P; Couch, FJ; Devilee, P; Tollenaar, RAEM; Seynaeve, C; Figueroa, J; Sherman, ME; Lissowska, J; Hewitt, S; Eccles, D; Hooning, MJ; Hollestelle, A; Martens, JWM; van Deurzen, CHM; kConFab Investigators; Bolla, MK; Wang, Q; Jones, M; Schoemaker, M; Wesseling, J; van Leeuwen, FE; Van 't Veer, L; Easton, D; Swerdlow, AJ; Dowsett, M; Pharoah, PD; Schmidt, MK; Garcia-Closas, M (2016-10-18)
      BACKGROUND:The value of KI67 in breast cancer prognostication has been questioned due to concerns on the analytical validity of visual KI67 assessment and methodological limitations of published studies. Here, we investigate ...
    • Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial. 

      Davarzani, N; Hutchins, GGA; West, NP; Hewitt, LC; Nankivell, M; Cunningham, D; Allum, WH; Smyth, E; Valeri, N; Langley, RE; Grabsch, HI (2018-06)
      AIMS:Neoadjuvant chemotherapy (NAC) remains an important therapeutic option for advanced oesophageal cancer (OC). Pathological tumour regression grade (TRG) may offer additional information by directing adjuvant treatment ...
    • Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. 

      Dowsett, M; Smith, IE; Ebbs, SR; Dixon, JM; Skene, A; Griffith, C; Boeddinghaus, I; Salter, J; Detre, S; Hills, M; Ashley, S; Francis, S; Walsh, G; A'Hern, R (2006-02)
      The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine treatment of breast cancer has become increasingly popular, particularly using the nuclear marker Ki67, and holds the ...
    • Prolonged treatment response in aggressive natural killer cell leukemia 

      Osuji, N; Matutes, E; Morilla, A; Del Giudice, I; Wotherspoon, A; Catovsky, D (TAYLOR & FRANCIS LTD, 2005-05)
      We describe a case of natural killer (NK) cell leukemia with acute presentation, systemic symptoms and hepatosplenomegaly. The uniform and aberrant phenotype of NK cells with infiltration of bone marrow and spleen was in ...
    • Prolymphocytic leukaemia and Hodgkin’s lymphoma 

      Naranjo, TA; Matutes, E; Martinez, JJ; Ferre, LF; Domingo, A; Princep, RB; Usach, TS (2002-09)
      We describe a case of B-prolymphocytic leukaemia (B-PLL) who, following a long-lasting remission with fluradabine, developed a Hodgkin’s lymphoma (HL) with bone marrow involvement. A 75-yr-old male was found to have a ...
    • Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper 

      Dungarwalla, M; Matutes, E; Dearden, CE (WILEY, 2008-06)
      Prolymphocytic leukaemias of B and T cell subtype are rare diseases. Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the ...
    • Prolymphocytic Leukemias 

      Krishnan, B; Matutes, E; Dearden, C (2006)
      T and B subtypes of prolymphocytic leukemias (PLLs) are rare, highly aggressive lymphoid malignancies with characteristic morphologic, immunophenotypical, cytogenetic, and molecular features. Recent studies have highlighted ...
    • Promoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer. 

      Orlando, G; Law, PJ; Cornish, AJ; Dobbins, SE; Chubb, D; Broderick, P; Litchfield, K; Hariri, F; Pastinen, T; Osborne, CS; Taipale, J; Houlston, RS (2018-10)
      Efforts are being directed to systematically analyze the non-coding regions of the genome for cancer-driving mutations1-6. cis-regulatory elements (CREs) represent a highly enriched subset of the non-coding regions of the ...
    • Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 

      Rescigno, P; Lorente, D; Bianchini, D; Ferraldeschi, R; Kolinsky, MP; Sideris, S; Zafeiriou, Z; Sumanasuriya, S; Smith, AD; Mehra, N; Jayaram, A; Perez-Lopez, R; Mateo, J; Parker, C; Dearnaley, DP; Tunariu, N; Reid, A; Attard, G; de Bono, JS (2016-11)
      The availability of multiple new treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A decline in prostate-specific antigen (PSA) is ...